Anthropic PBC has released Claude Science, a new software tool designed to automate research tasks in biology and chemistry, including protein structure prediction, the company announced Tuesday. The tool integrates over 60 scientific databases and allows scientists to use plain language queries to automate multistep processes without consulting multiple sources individually.
Claude Science Features and Availability
Claude Science is being offered as a beta version to Anthropic's paid users. The software brings together commonly used scientific tools and databases, enabling researchers to ask questions and receive answers efficiently. According to Anthropic, the goal is to reduce tedious aspects of scientific work by simplifying complex workflows.
The tool uses existing Claude models, such as Opus 4.8, released in May. Outputs include traceable details that allow scientists to verify accuracy, and generated images include metadata on how they were created.
Strategic Context and Market Impact
Anthropic and rival OpenAI have been developing AI tools to streamline professional tasks across sectors like finance, science, and healthcare, aiming to attract business customers and justify high valuations. Anthropic, valued at US$965 billion, is moving toward an initial public offering as soon as this fall.
Anthropic's previous tools have rattled markets; in February, the introduction of Claude Cowork for legal automation triggered a US$1 trillion stock market rout. The company expects to announce Claude Science at a San Francisco event featuring CEO Dario Amodei, along with executives from Bristol-Myers Squibb and Novartis.
Recent Regulatory Challenges
The release comes less than two weeks after Anthropic disabled access to its most advanced AI models—Fable 5 and Mythos 5—due to a Trump administration order to keep the technology from foreign nationals. On Friday, Anthropic won U.S. approval to restore some access to Mythos 5 after addressing national security concerns; restrictions on Fable 5 remain unchanged.
